MP41-05 LIQUID-BIOPSY BASED NOVEL mRNA GENOMIC TEST FOR EARLY DETECTION, PROGNOSIS AND MONITORING OF PROSTATE CANCER: A MULTICENTER STUDY

You have accessJournal of UrologyProstate Cancer: Markers I (MP41)1 May 2024MP41-05 LIQUID-BIOPSY BASED NOVEL mRNA GENOMIC TEST FOR EARLY DETECTION, PROGNOSIS AND MONITORING OF PROSTATE CANCER: A MULTICENTER STUDY Yutaka Hashimoto, Shiv Verma, Guoren Deng, Dharam P. Chauhan, Sujit Nair, Dimple Chakravarty, Hirofumi Yoshino, Junya Arima, Shuichi Tatarano, Yutong Liu, Koji Hatano, Yogesh Shivakumar, Mithua Ghosh, Raghunath S. Krishnappa, Chitra Chandran, Narasimhan Ragavan, Hideki Enokida, Norio Nonomura, K. C. Balaji, Sudhir K. Rawal, Ashutosh K. Tewari, Rajvir Dahiya, and Sanjay Gupta Yutaka HashimotoYutaka Hashimoto , Shiv VermaShiv Verma , Guoren DengGuoren Deng , Dharam P. ChauhanDharam P. Chauhan , Sujit NairSujit Nair , Dimple ChakravartyDimple Chakravarty , Hirofumi YoshinoHirofumi Yoshino , Junya ArimaJunya Arima , Shuichi TataranoShuichi Tatarano , Yutong LiuYutong Liu , Koji HatanoKoji Hatano , Yogesh ShivakumarYogesh Shivakumar , Mithua GhoshMithua Ghosh , Raghunath S. KrishnappaRaghunath S. Krishnappa , Chitra ChandranChitra Chandran , Narasimhan RagavanNarasimhan Ragavan , Hideki EnokidaHideki Enokida , Norio NonomuraNorio Nonomura , K. C. BalajiK. C. Balaji , Sudhir K. RawalSudhir K. Rawal , Ashutosh K. TewariAshutosh K. Tewari , Rajvir DahiyaRajvir Dahiya , and Sanjay GuptaSanjay Gupta View All Author Informationhttps://doi.org/10.1097/01.JU.0001008896.93851.5b.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Current screening tools, including prostate-specific antigen (PSA) and clinico-pathologic parameters, have limitations in the diagnosis and prognosis of prostate cancer. This study examined whether mRNA-genomic biomarkers can improve screening and monitoring of prostate cancer. METHODS: We identified a panel of 25 prostate cancer-related genes through rigorous bioinformatics, computational analyses and genetic testing. These tests, developed by Geneverify Inc. (Hayward, CA; U.S. patent #10801072 and 10822661) were utilized and optimized by qRT-PCR to determine the diagnostic and prognostic ability of prostate cancer using blood and tissues. The log2-fold increase in gene expression was used to assign the risk score to individual patients. ROC (receiver operator characteristic), AUC (area under ROC curve), and calibration curves were generated to display the overall performance and discrimination ability to separate cancer and non-cancer specimens. RESULTS: A total of 429 prostate cancer patients (135 blood and 294 tissue samples) and 130 normal samples were analyzed in this study. The eligibility criteria were to collect blood and surgical specimens from patients with prostate cancer from 9 hospitals. The study endpoints were to analyze mRNA genomic profiling and correlate with clinico-pathologic parameters of the patients. In the blood, a 25-panel gene-set separated prostate cancer patients (n=135) from non-cancer (n=30), AUC=0.906 sensitivity=90% and specificity=91%. Assessment of tissue specimens from benign (n=100) and cancer patients (n=284) showed similar results with AUC=0.9514 sensitivity=95% and specificity=94%. Interestingly, patients with Gleason grades (GS) >7 showed higher expression of these genes compared to GS <7, suggesting the prognostic ability of the gene-set. When we compared the gene expression in blood verses tissues, there were similar patterns, suggesting that blood can be used for screening, diagnosis and risk assessment of prostate cancer. CONCLUSIONS: To our knowledge, this is the first study to investigate the role of mRNA-based genomic signatures for screening, early diagnosis and prognosis of prostate cancer using blood samples. Our data suggest, that blood mRNA-genomic profiling developed by Geneverify, has the ability to diagnose prostate cancer and stratify patients into distinct prognostic groups, which in turn help in making better treatment strategies. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e674 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Yutaka Hashimoto More articles by this author Shiv Verma More articles by this author Guoren Deng More articles by this author Dharam P. Chauhan More articles by this author Sujit Nair More articles by this author Dimple Chakravarty More articles by this author Hirofumi Yoshino More articles by this author Junya Arima More articles by this author Shuichi Tatarano More articles by this author Yutong Liu More articles by this author Koji Hatano More articles by this author Yogesh Shivakumar More articles by this author Mithua Ghosh More articles by this author Raghunath S. Krishnappa More articles by this author Chitra Chandran More articles by this author Narasimhan Ragavan More articles by this author Hideki Enokida More articles by this author Norio Nonomura More articles by this author K. C. Balaji More articles by this author Sudhir K. Rawal More articles by this author Ashutosh K. Tewari More articles by this author Rajvir Dahiya More articles by this author Sanjay Gupta More articles by this author Expand All Advertisement PDF downloadLoading ...